Zacks Investment Research cut shares of Ra Pharmaceuticals (NASDAQ:RARX) from a hold rating to a sell rating in a report issued on Thursday morning, Zacks.com reports.

According to Zacks, “Ra Pharmaceuticals, Inc. is a biopharmaceutical company. It involved in the discovery and development of novel therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. Ra Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “

Other equities analysts have also recently issued reports about the company. Leerink Swann set a $5.00 price objective on Tocagen and gave the stock a hold rating in a research note on Wednesday, May 22nd. SunTrust Banks raised their price objective on Wix.Com to $154.00 and gave the stock a buy rating in a research note on Friday, May 17th. Svb Leerink initiated coverage on Ra Pharmaceuticals in a research note on Wednesday, May 22nd. They set an outperform rating and a $33.00 price objective on the stock. Raymond James reduced their price objective on Marathon Petroleum from $90.00 to $85.00 and set a strong-buy rating on the stock in a research note on Wednesday, April 10th. Finally, Jefferies Financial Group restated a buy rating and set a GBX 1,453 ($18.99) price objective on shares of in a research note on Tuesday, June 18th. One equities research analyst has rated the stock with a sell rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. Ra Pharmaceuticals presently has an average rating of Buy and an average target price of $37.73.

RARX stock opened at $33.53 on Thursday. Ra Pharmaceuticals has a twelve month low of $8.67 and a twelve month high of $34.50. The company has a debt-to-equity ratio of 0.02, a current ratio of 20.10 and a quick ratio of 20.10. The firm has a market capitalization of $1.42 billion, a P/E ratio of -16.28 and a beta of 1.22. The stock’s 50 day moving average is $27.07.

Ra Pharmaceuticals (NASDAQ:RARX) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.02. On average, research analysts forecast that Ra Pharmaceuticals will post -1.98 EPS for the current fiscal year.

In other Ra Pharmaceuticals news, insider Simon Read sold 10,000 shares of the firm’s stock in a transaction on Tuesday, June 18th. The stock was sold at an average price of $22.25, for a total value of $222,500.00. Following the sale, the insider now directly owns 8,521 shares in the company, valued at $189,592.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Alonso Ricardo sold 2,857 shares of the firm’s stock in a transaction on Friday, June 21st. The shares were sold at an average price of $23.72, for a total value of $67,768.04. Following the completion of the sale, the insider now owns 11,428 shares in the company, valued at $271,072.16. The disclosure for this sale can be found here. Insiders have sold 33,452 shares of company stock worth $970,463 over the last 90 days. 4.30% of the stock is currently owned by company insiders.

A number of hedge funds have recently bought and sold shares of RARX. BlackRock Inc. lifted its stake in Ra Pharmaceuticals by 29.0% in the fourth quarter. BlackRock Inc. now owns 2,645,261 shares of the company’s stock valued at $48,142,000 after buying an additional 595,328 shares during the last quarter. FMR LLC lifted its stake in Ra Pharmaceuticals by 454.2% in the fourth quarter. FMR LLC now owns 413,389 shares of the company’s stock valued at $7,524,000 after buying an additional 338,801 shares during the last quarter. Millennium Management LLC lifted its stake in Ra Pharmaceuticals by 407.0% in the fourth quarter. Millennium Management LLC now owns 412,066 shares of the company’s stock valued at $7,500,000 after buying an additional 330,788 shares during the last quarter. Spark Investment Management LLC bought a new stake in Ra Pharmaceuticals in the first quarter valued at $3,458,000. Finally, Rhenman & Partners Asset Management AB bought a new stake in Ra Pharmaceuticals in the first quarter valued at $3,360,000. Institutional investors own 94.97% of the company’s stock.

Ra Pharmaceuticals Company Profile

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

Read More: What are momentum indicators and what do they show?

Get a free copy of the Zacks research report on Ra Pharmaceuticals (RARX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.